These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1754 related items for PubMed ID: 31062162
21. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Zhong Q, Zhu X, Li L, Qu S, Liang Z, Zeng F, Pan X. Oncotarget; 2017 Jun 13; 8(24):39683-39694. PubMed ID: 28147309 [Abstract] [Full Text] [Related]
22. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area. Fangzheng W, Chuner J, Haiyan Q, Quanquan S, Zhimin Y, Tongxin L, Jiping L, Peng W, Kaiyuan S, Zhenfu F, Yangming J. Medicine (Baltimore); 2019 Dec 13; 98(51):e18484. PubMed ID: 31861031 [Abstract] [Full Text] [Related]
23. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW. Ann Oncol; 2018 Sep 01; 29(9):1972-1979. PubMed ID: 30016391 [Abstract] [Full Text] [Related]
24. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Liu SL, Sun XS, Yan JJ, Chen QY, Lin HX, Wen YF, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Li XY, Lin C, Du YY, Yang ZC, Xiao BB, Yang JH, Tang LQ, Guo L, Mai HQ. Radiother Oncol; 2019 Aug 01; 137():83-94. PubMed ID: 31078941 [Abstract] [Full Text] [Related]
25. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Li Y, Tang LQ, Liu LT, Guo SS, Liang YJ, Sun XS, Tang QN, Bei JX, Tan J, Chen S, Ma J, Zhao C, Chen QY, Mai HQ. Cancer Res Treat; 2018 Oct 01; 50(4):1304-1315. PubMed ID: 29334605 [Abstract] [Full Text] [Related]
26. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Wu SX, Bai YR, Ke LR, Qiu WZ, Liang H, Liu GY, Miao JJ, Li WZ, Lv SH, Chen X, Zhao C, Xiang YQ, Guo X. Lancet Oncol; 2021 May 01; 22(5):716-726. PubMed ID: 33857411 [Abstract] [Full Text] [Related]
27. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study. Li SW, Wang H, Liu ML, Zhang HB, Xiang YQ, Lv X, Xia WX, Zeng MS, Mai HQ, Hong MH, Guo X. Med Oncol; 2013 Mar 01; 30(1):322. PubMed ID: 23254962 [Abstract] [Full Text] [Related]
28. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. Huang PY, Zeng Q, Cao KJ, Guo X, Guo L, Mo HY, Wu PH, Qian CN, Mai HQ, Hong MH. Eur J Cancer; 2015 Sep 01; 51(13):1760-70. PubMed ID: 26093812 [Abstract] [Full Text] [Related]
29. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma. Chen R, Lu Y, Zhang Y, He R, Tang F, Yuan W, Li Y, Zhang X. Medicine (Baltimore); 2021 Oct 22; 100(42):e27475. PubMed ID: 34678878 [Abstract] [Full Text] [Related]
30. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. Yi J, Huang X, Gao L, Luo J, Zhang S, Wang K, Qu Y, Xiao J, Xu G. Radiat Oncol; 2014 Feb 18; 9():56. PubMed ID: 24533569 [Abstract] [Full Text] [Related]
31. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Zhang J, Chen S, Li G, Zhang W, Qin T, Yin P, Huang H, Jiang H. Cancer Chemother Pharmacol; 2017 Jun 18; 79(6):1087-1097. PubMed ID: 28429051 [Abstract] [Full Text] [Related]
32. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Xu C, Sun R, Tang LL, Chen L, Li WF, Mao YP, Zhou GQ, Guo R, Lin AH, Sun Y, Ma J, Hu WH. Oral Oncol; 2018 Mar 18; 78():37-45. PubMed ID: 29496056 [Abstract] [Full Text] [Related]
33. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ, Hong MH. Oral Oncol; 2012 Oct 18; 48(10):1038-1044. PubMed ID: 22591726 [Abstract] [Full Text] [Related]
34. Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China. Zang J, Xu M, Li C, Zhao L, Luo S, Wang J, Shi M. J Cancer Res Clin Oncol; 2020 Sep 18; 146(9):2369-2378. PubMed ID: 32363479 [Abstract] [Full Text] [Related]
35. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3. Kawahira M, Yokota T, Hamauchi S, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H. Jpn J Clin Oncol; 2017 Aug 01; 47(8):705-712. PubMed ID: 28431119 [Abstract] [Full Text] [Related]
36. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis. Zeng Q, Wang J, Lv X, Li J, Yin LJ, Xiang YQ, Guo X. BMC Cancer; 2016 Aug 30; 16(1):693. PubMed ID: 27577729 [Abstract] [Full Text] [Related]
37. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level. Liu SL, Sun XS, Xie HJ, Chen QY, Lin HX, Liang H, Liang YJ, Li XY, Yan JJ, Lin C, Yang ZC, Guo SS, Liu LT, Tang QN, Du YY, Tang LQ, Guo L, Mai HQ. BMC Cancer; 2020 Feb 03; 20(1):89. PubMed ID: 32013967 [Abstract] [Full Text] [Related]
38. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma. Zhang L, Shan GP, Li P, Cheng PJ. Med Oncol; 2015 Mar 03; 32(3):41. PubMed ID: 25631634 [Abstract] [Full Text] [Related]
39. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial. Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, Qin G, Kong X, Mo Y, Zhang R, Liu Z, Xie Y, Ruan X, Jiang W. JAMA Oncol; 2024 Apr 01; 10(4):456-463. PubMed ID: 38329737 [Abstract] [Full Text] [Related]
40. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Su Z, Mao YP, Tang J, Lan XW, OuYang PY, Xie FY. Tumour Biol; 2016 Apr 01; 37(4):4429-38. PubMed ID: 26499947 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]